As part of our quarterly pharmaceutical industry review, we are pleased to share an update on merger and acquisition activity to help our clients understand the market dynamics impacting pharmaceutical manufacturers, service providers, and their supplier relationships.

Key M&A highlights in Q2 2026

  • ✓ The biopharma M&A supercycle intensified in Q2 2026, with deal value for the year reaching approximately $134 billion across 33 transactions of $1 billion or more by late June—already surpassing the full-year 2025 total of $112 billion in roughly half the time—before the final week of the quarter added several more megadeals to the tally. If the pace holds, 2026 could become the strongest year for biopharma dealmaking since before the pandemic.
  • ✓ The final week of June delivered an extraordinary cluster of megadeals, including AbbVie’s $10.9 billion acquisition of Apogee Therapeutics, Merck KGaA’s $11.3 billion purchase of Bio-Techne, and Ipsen’s and Zymeworks’s respective deals—vividly illustrating the dealmaking urgency across the sector.
  • ✓ The $300 billion patent cliff remains the primary engine of dealmaking. With over $300 billion in branded pharmaceutical revenue exposed to loss of exclusivity this decade, large pharma companies continue deploying substantial cash reserves to acquire late-stage, de-risked assets that can replace revenue from expiring blockbuster patents.
  • ✓ Oncology led deal value in the first half of 2026, followed closely by immunology and inflammation. Next-generation modalities—including antibody-drug conjugates (ADCs), RNA therapeutics, and precision kinase inhibitors—drove much of the strategic activity, reflecting buyers’ focus on differentiated science.
  • ✓ Life sciences tools and services consolidation reached new heights with Merck KGaA’s $11.3 billion Bio-Techne acquisition—the largest life science tools transaction of 2026 and Merck KGaA’s biggest deal in over a decade—signaling that reagent, bioprocessing, and cell therapy supply capabilities have become strategic priorities.
  • ✓ Private equity deepened its footprint in pharma, headlined by the CVC-Groupe Bruxelles Lambert consortium’s approximately $12.4 billion take-private offer for Italy’s Recordati—one of the largest European healthcare transactions of the year and a continuation of the ongoing “PE-ization of pharma.”
  • ✓ The bolt-on acquisition remained the market’s sweet spot, with buyers favoring $1 billion to $10 billion transactions targeting Phase 2 and Phase 3 assets that can be rapidly integrated into existing commercial platforms while minimizing integration risk. Broad platform stories no longer justify premium pricing—capital is following the science.
  • ✓ For vendors and service providers, this consolidation wave carries direct implications: when large pharma acquires a mid-cap biotech, the acquired company’s vendor relationships are rationalized, duplicated infrastructure is cut, and procurement shifts to the acquirer’s preferred suppliers—vendor rationalization at scale.

2026 Q2 Activity Highlights

In the second quarter of 2026, pharmaceutical industry M&A activity remained exceptionally robust, with a notable concentration of transformative transactions announced in late June. The following significant deals were announced or advanced, along with one notable transaction announced just after quarter-end:

1. Sun Pharma to acquire Organon for $11.75 billion (April 2026)

Sun Pharmaceutical Industries announced on April 26, 2026 a definitive agreement to acquire Organon & Co. for $14.00 per share in an all-cash transaction with an enterprise value of approximately $11.75 billion—a 103% premium to Organon’s unaffected closing price. This is Sun Pharma’s largest acquisition and India’s most significant outbound pharmaceutical deal to date.

Organon, spun off from Merck in 2021, brings a portfolio of more than 70 products across women’s health and general medicines, including a growing biosimilars business. For the year ended December 31, 2025, Organon reported $6.2 billion in revenue and $1.9 billion in adjusted EBITDA. The acquisition supports Sun Pharma’s strategy to grow its innovative medicines business and enter the biosimilar market.

The transaction will take Organon private and delist it from the NYSE. It is backed by committed debt financing and is expected to close in early 2027, subject to shareholder approval and global antitrust and foreign direct investment clearances.

2. Merck KGaA to acquire Bio-Techne for $11.3 billion (June 2026)

Merck KGaA, Darmstadt, Germany announced on June 25, 2026 a definitive agreement to acquire Bio-Techne Corporation, a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion (EUR 9.9 billion) and a 36% premium to Bio-Techne’s one-month volume-weighted average price.

This represents Merck KGaA’s largest acquisition in over a decade—its biggest since the $17 billion Sigma-Aldrich deal in 2014. Bio-Techne supplies research reagents, proteins, antibodies, analytical instruments, and other tools widely used by scientists and drug developers. The deal strengthens Merck KGaA’s position in multi-omics, spatial biology, cell and gene therapy, and precision diagnostics, with the advanced therapeutics segment being its fastest-growing area at over 20% growth.

The transaction reinforces Merck KGaA’s life sciences business as its primary growth driver. Merck KGaA expects annual cost synergies of approximately EUR 140 million, fully realized by year three, and anticipates the deal being immediately accretive to sales growth. It is expected to close in late 2026 or early 2027.

3. AbbVie to acquire Apogee Therapeutics for $10.9 billion (June 2026)

AbbVie announced on June 22, 2026 a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, valuing the company at a total equity value of approximately $10.9 billion—a roughly 49% premium to the prior closing price. The implied transaction value is approximately $10.1 billion net of estimated cash acquired.

The acquisition adds Apogee’s diverse pipeline of clinical-stage candidates across inflammatory and immunological diseases. Its lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13 in development for atopic dermatitis, with additional potential in asthma and eosinophilic esophagitis. The pipeline also includes APG273, a potential best-in-category long-acting combination targeting IL-13 and TSLP for asthma.

The deal complements AbbVie’s existing immunology leadership—built around Skyrizi and Rinvoq—and accelerates its clinical presence in the respiratory space as it manages lifecycle transitions in its immunology franchise. The transaction is expected to close in Q3 2026, subject to Apogee shareholder approval and regulatory clearances.

4. GSK to acquire Nuvalent for $10.6 billion (June 2026)

GSK announced on June 9, 2026 a definitive agreement to acquire Nuvalent, Inc., a Boston-based clinical-stage biopharmaceutical company focused on precisely targeted oncology therapies, for $124 per share in cash—a total value of approximately $10.6 billion and a 40% premium to the prior close. This is GSK’s third acquisition of 2026, bringing its total 2026 M&A spend to nearly $14 billion.

The multi-product oncology deal centers on two late-stage, potentially best-in-class inhibitors for non-small cell lung cancer (NSCLC): zidesamtinib (ROS1) and neladalkib (ALK), both under FDA review with target decision dates of September 18 and November 27, 2026, respectively. Both hold Breakthrough Therapy and Orphan Drug designations. A third asset, NVL-330, is a HER2 inhibitor in Phase 1 trials.

The acquisition accelerates GSK’s entry into lung cancer and provides a platform for expansion with Ris-Rez, GSK’s B7-H3 antibody-drug conjugate in Phase 3 development. GSK expects the deal to be accretive to sales and core operating profit in 2027. The transaction was completed in July 2026.

5. CVC-GBL consortium to take Recordati private for approximately $12.4 billion (May 2026)

CVC Capital Partners and Groupe Bruxelles Lambert signed binding agreements on May 22, 2026 for a voluntary cash offer of EUR 51.29 per share for Italy’s Recordati, valuing the drugmaker at more than $12 billion (approximately EUR 10.7 billion)—one of the largest European healthcare transactions of the year. CVC first expressed interest via a non-binding indication in late March 2026.

CVC, which acquired its controlling stake in family-run Recordati in 2018, aims to take the company private and delist it from the Italian Stock Exchange. Recordati—in its 100th year of operation—has more than doubled its sales over the last decade, reporting EUR 2.6 billion in total sales in 2025. The company has a notable rare disease franchise, which CVC has reportedly explored as one option for potential future divestment.

The offer, joined by co-investors including Groupe Bruxelles Lambert, is expected to close in Q4 2026 subject to antitrust, foreign direct investment, and foreign subsidies regulation approvals. The transaction exemplifies the continued expansion of private equity into established pharmaceutical platforms.

6. Ipsen to acquire Kartos Therapeutics for up to $1.75 billion (June 2026)

Ipsen announced on June 29, 2026 a definitive agreement to acquire Kartos Therapeutics for $450 million upfront, with Kartos shareholders eligible to receive up to an additional $1.3 billion in regulatory and sales-based milestone payments.

The acquisition adds navtemadlin, a Phase 3 oral MDM2 inhibitor designed to restore the natural tumor-suppressing function of p53. Navtemadlin is being evaluated in the global Phase 3 POIESIS trial as an add-on to standard-of-care ruxolitinib in intermediate- and high-risk TP53 wild-type myelofibrosis patients with suboptimal response—a population with meaningful unmet need.

The deal strengthens Ipsen’s late-stage hemato-oncology pipeline, with Phase 3 POIESIS top-line data expected in 2027 and a potential launch as early as 2028. It is expected to be accretive to Ipsen’s core operating income from 2029 and to close by the end of Q3 2026.

7. Zymeworks to acquire Theravance Biopharma for approximately $929 million (June 2026)

Zymeworks announced on June 29, 2026 a definitive agreement to acquire Theravance Biopharma for $17.00 per share in cash, representing a total transaction value of approximately $929 million, plus a contingent value right tied to future monetization of ampreloxetine.

The acquisition centers on Yupelri (revefenacin), the only approved nebulized, once-daily long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD, marketed in the U.S. since 2019 through a collaboration with Viatris in which Theravance holds a 35% U.S. net profit share. The deal represents a notable example of a public biotech acquiring another to add near-term commercial cash flow rather than a classic big pharma pipeline takeout.

Zymeworks plans post-close restructuring to lower R&D and G&A expenses, prioritizing Yupelri-linked profitability. The transaction is expected to close in the second half of 2026, pending regulatory and Theravance shareholder approval.

8. Novartis to acquire Myricx Bio for up to $1.5 billion (announced July 6, 2026)

Just after the quarter closed, Novartis announced on July 6, 2026 an agreement to acquire UK-based Myricx Bio for $1.1 billion upfront plus up to $400 million in potential milestone payments, continuing its cadence of bolt-on acquisitions to offset looming patent expirations.

The deal gives Novartis access to a differentiated ADC payload platform—specifically, a potential first-in-class N-myristoyltransferase (NMT) inhibitor payload with applicability across multiple solid tumor settings. Rather than acquiring another target-specific ADC, Novartis is buying into next-generation payload biology that could overcome limitations of established TOPO-1-based ADC approaches.

The acquisition reinforces sustained strategic appetite for next-generation oncology modality platforms. It is expected to close in the second half of 2026, subject to customary closing conditions and regulatory approvals.

Looking ahead

With biopharma M&A already exceeding the full-year 2025 total by mid-2026, industry analysts anticipate continued momentum through the second half of the year, though a deteriorating interest rate environment following recent geopolitical and inflationary pressures may temper the pace somewhat. PwC analysts expect additional private equity-led carve-outs of non-core assets and franchises from large pharmaceutical companies in the second half of 2026—transactions that could create new standalone platforms in areas such as CDMO, CRO, and bioprocessing and fuel further bolt-on activity.

For Zensights clients and ZEN members, the practical takeaway remains consistent: each major acquisition triggers vendor rationalization at the acquired company, shifting procurement toward the acquirer’s preferred suppliers—while every carve-out creates a new standalone entity with a blank procurement slate. Monitoring these transactions closely offers early signals for both risk (displaced vendor relationships) and opportunity (newly independent platforms seeking partners).